Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 251-882-0 | CAS number: 34206-40-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key study: Based on the read-across approach from experimental results on analogue butanone oxime, the NOAEL for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime for 13 weeks repeated dose toxicity by oral route in rats was estimated to be 333.54 ppm (26.73 and 32.07 mg/kg bw/day for males and females respectively).
Supporting study: Based on the read-across approach from experimental results on analogue butanone oxime, the NOAEL for butan-2-one-O,O',O''-(methylsilanetriyl)oxime for 13 weeks repeated dose toxicity by oral route in mice was estimated to be 720.89 ppm (126.88 mg/kg bw/day) for males and 1441.79 ppm (392.17 mg/kg bw/day) for females.
Key study: Based on the read-across approach from experimental results on analogue butanone oxime, the NOEL for butan-2-one-O,O',O''-(methylsilanetriyl)oxime for 28 days repeated dose toxicity by oral route in rats was estimated to be 4.61 mg/kg/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
The target substance TOS is an oxime silane that undergoes rapid hydrolysis in aqueous to MEKO and the corresponding silanol. At the same time, silanols undergo continuous condensation reaction to produce higher molecular weight siloxanes which are in the molecular weight range large enough to be considered biologically unavailable. Therefore, the toxicity of TOS is due to the hydrolysis product MEKO and their values are comparable.
See attached reporting format. - Reason / purpose for cross-reference:
- read-across source
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- (males and females at >=2672.61)
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- (males and females at >=2672.61)
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- (males at >=1336.30 ppm, females at >=2672.61 ppm)
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- (not significant)
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- (males and females at >= 333.54 ppm)
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- (males at >= 333.54 ppm, females at >=668.15 ppm)
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- (males and females at >=668.15 ppm)
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- (males and females at >= 668.15 ppm)
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Based on experimental results obtained with the analogue substance butanone oxime in rats after 13 weeks oral administration where the NOAEL for erythrotoxicity was 312 ppm and the NOAEL for olfactory epithelium degeneration was 1250 ppm, the read-across approach was applied and the NOAEL for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was estimated to be 333.54 ppm for erythrotoxicity and 1336.30 ppm for olfactory epithelium degeneration.
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- (erythrotoxicity)
- Effect level:
- 333.54 ppm
- Based on:
- test mat.
- Remarks:
- (analogue subtance)
- Sex:
- male/female
- Basis for effect level:
- other: (based on read-across approach from experimental data on analogue butanone oxime) (basis for effect: anemia)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- (nose)
- Effect level:
- 1 336.3 ppm
- Based on:
- test mat.
- Remarks:
- (analogue substance)
- Sex:
- male/female
- Basis for effect level:
- other: (based on read-across approach from experimental data on analogue butatone oxime) (basis for effect: olfactory epithelium degeneration)
- Key result
- Critical effects observed:
- not specified
- Conclusions:
- Based on the read-across approach from experimental results on analogue butanone oxime, the NOAEL for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime for 13 weeks repeated dose toxicity by oral route in rats was estimated to be 333.54 ppm (26.73 and 32.07 mg/kg bw/day for males and females respectively) for erythrotoxicity and 1336.30 ppm (106.90 and 128.29 mg/kg bw/day for males and females respectively) for olfactory epithelium degeneration.
- Executive summary:
A 90 days repeated dose toxicity test was performed on analogue substance butanone oxime in accordance with an equivalent method to OECD Guideline 408. After 13 weeks oral administration of analogue MEKO to rats up to 5000 ppm (up to 280 mg/kg bw/day in males and up to 335 mg/kg/bw/day), the NOAEL for erythrotoxicity was determined to be 312 ppm (25 and 30 mg/kg bw/day in males and females respectively) and the NOAEL for olfactory epithelium degeneration was determined to be 1250 ppm (100 and 120 mg/kg bw/day in males and females respectively).
Based on these results, the read-across approach was applied and the NOAEL for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime for 13 weeks repeated dose toxicity by oral route in rats was estimated to be 333.54 ppm (26.73 and 32.07 mg/kg bw/day for males and females respectively) for erythrotoxicity and 1336.30 ppm (106.90 and 128.29 mg/kg bw/day for males and females respectively) f or olfactory epithelium degeneration.
Reference
The concentrations used in the study on the analogue substance and the read-across approch estimation are as follows:
Unit | Sex | MEKO | TOS |
ppm | Male/female | 312,00 | 333,54 |
625,00 | 668,15 | ||
1250,00 | 1336,30 | ||
2500,00 | 2672,61 | ||
5000,00 | 5345,21 | ||
mg/kg bw/day | Male | 25,00 | 26,73 |
50,00 | 53,45 | ||
100,00 | 106,90 | ||
175,00 | 187,08 | ||
280,00 | 299,33 | ||
mg/kg bw/day | Female | 30,00 | 32,07 |
65,00 | 69,49 | ||
120,00 | 128,29 | ||
215,00 | 229,84 | ||
335,00 | 358,13 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 26.73 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Three studies are available on an analogue substance (two 90d and a 28 day repeated dose toxicity studies) with a Klimisch score = 1. The overall quality of the database was determined as appropriate for assessment.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
ORAL Repeated dose toxicity study:
Key study: Read-across from experimental data on analogue butatone oxime: 90 days oral repeated dose toxicity study in rats (test method similar to OECD 408):
In the study performed on analogue butatone onxime, groups of 10 rats per sex were given drinking water containing 0, 312, 625, 1250, 2500, or 5000 ppm (25, 50, 100, 175, 175, 280 mg/kg bw/day in males and 30, 65, 120, 215, 335 mg/kg bw/day in females) of test item. All rats survived until the end of the study. NOAEL for the most sensitive parameter (erythrotoxicity) for rats after 90 days of exposure to butanone oxime was determined to be 312 ppm (25 mg/kg bw/day males and 30 mg/kg bw/day females). Based on these results, the read-across approach was applied and the NOAEL for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was estimated to be 333.54 ppm (26.73 mg/kg bw/day in males and 32.07 mg/kg bw/day in females).
Supporting study: Read-across from experimental data on analogue substance butanone oxime: 90 days oral repeated dose toxicity study in mice (test method similar to OECD 408):
In the study performed on analogue butanone oxime, groups of 10 mice per sex were given drinking water containing 0 (control), 625, 1,250, 2,500, 5,000, or 10,000 ppm (110, 200, 515, 755, 1330 mg/kg bw/day in males and 145, 340, 630, 1010 and 3170 mg/kg bw/day in females) of test substance. All mice survived until the end of the study. The NOAEL after 90 days of exposure to butanone oxime based on the most sensitive parameter was determined to be 625 ppm (110 mg/kg bw/day) for male mice (basis for effect: hyperplasia of the urinary bladder transitional epithelium) and 1250 ppm (635 mg/kg bw/day) for female mice (basis for effect: infiltration of inflammatory cells into the underlying submucosa in the urinary bladder and degeneration of the olfactoy epithelium). Based on these results, the read-across approach was applied and the NOAEL for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was estimated to be 668.15 ppm (117.59 mg/kg bw/day) for males and 1336.30 ppm (363.47 mg/kg bw/day) for females.
Key study: Read-across from experimental data on analogue substance butanone oxime: 28 days oral repeated dose toxicity study in rats (test method similar to OECD 407):
In the study performed by the Japanese authorities, 7 rats per sex and per dose were orally exposed to the analogue substance butanone oxime at 0 (control), 4, 20 and 100 mg/kg bw/day doses during 28 days. The NOEL for repeat dose toxicity for both males and females was considered to be both 4 mg/kg/day (basis for effect: effects on erythrocyte series, spleen weight increase, hemosiderin granules in the liver (only in females)). Based on these results, the read-across approach was applied and the NOEL for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was estimated to be 4.28 mg/kg bw/day.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The study with the longest duration (90-days) performed and lowest NOAEL was chosen.
Justification for classification or non-classification
Based on available data and in accordance with CLP Regulation (EC) No 1272/2008, the substance butan-2-one O,O',O'',O'''-silanetetrayltetraoxime is classified as STOT Rep. Exp. 2 since the ignificant toxic effects were observed in a 90-day repeated-dose study (oral) conducted in experimental animals within value ranges 10 -100 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.